Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
LPTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $4.79
Previous CloseN/A
Volume72.74K
Average Volume (3M)1.23M
Market Cap
$18.50M
Enterprise Value$43.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 24, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding38,317,898
10 Day Avg. Volume717,820
30 Day Avg. Volume1,230,462
Standard Deviation0.37
R-Squared0.00041
Alpha0.00587
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-101.78
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$2.13Price Target Upside343.75% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Leap Therapeutics News
PremiumCompany Announcements
Leap Therapeutics Reports Q3 2024 Progress and Financials---
Bulls Say, Bears Say
Bulls Say
Efficacy DataEncouraging data in a niche CRC population showed a higher objective response rate for sirexatamab compared to the control group.
Future PotentialSuccess in either trial could move the stock several times higher.
Regulatory PathwayManagement believes the data in CRC is strong enough to initiate a conversation with FDA to seek a regulatory pathway based on the positive objective response data in DeFianCe.
Bears Say
Clinical Data UpdatesLimited insight into ongoing activities and no major clinical data updates expected for at least six months.
Financial PositionThe company's current cash position is insufficient to fund a Phase 3 clinical program, which may require seeking a partnership.
Market PotentialSirexatamab did not show benefit in gastroesophageal/gastric cancer, lowering the overall market potential of the drug.
---
Ownership Overview
6.24% Insiders
3.46% Mutual Funds
38.53% Other Institutional Investors
46.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LPTX FAQ
What was Leap Therapeutics Inc’s price range in the past 12 months?
Leap Therapeutics Inc lowest stock price was $0.47 and its highest was $4.79 in the past 12 months.
What is Leap Therapeutics Inc’s market cap?
Leap Therapeutics Inc’s market cap is $18.50M.
When is Leap Therapeutics Inc’s upcoming earnings report date?
Leap Therapeutics Inc’s upcoming earnings report date is Mar 24, 2025 which is in 30 days.
How were Leap Therapeutics Inc’s earnings last quarter?
Leap Therapeutics Inc released its earnings results on Nov 13, 2024. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.494 by $0.054.
Is Leap Therapeutics Inc overvalued?
According to Wall Street analysts Leap Therapeutics Inc’s price is currently Undervalued.
Does Leap Therapeutics Inc pay dividends?
Leap Therapeutics Inc does not currently pay dividends.
What is Leap Therapeutics Inc’s EPS estimate?
Leap Therapeutics Inc’s EPS estimate is -0.41.
How many shares outstanding does Leap Therapeutics Inc have?
Leap Therapeutics Inc has 38,317,898 shares outstanding.
What happened to Leap Therapeutics Inc’s price movement after its last earnings report?
Leap Therapeutics Inc reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.494. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Leap Therapeutics Inc?
Currently, no hedge funds are holding shares in LPTX
---
Leap Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.13 (343.75% Upside)
$2.13 (343.75% Upside)
Blogger Sentiment
Bullish
LPTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $18.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.42%
12-Months-Change
Fundamentals
Return on Equity
-106.79%
Trailing 12-Months
Asset Growth
-21.67%
Trailing 12-Months
Company Description
Leap Therapeutics Inc
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
---
LPTX Stock 12 Month Forecast
Average Price Target
$2.13
▲(343.75% Upside)
Technical Analysis
Best Analysts Covering LPTX
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-37.11%
assigned a buy rating 25 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.11% per trade.
---